HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Guangzhou Pharmaceuticals - The Risk Points Gradually Emerged

Pre-IPO Keymed Biosciences - Challenges Are Inevitable Despite Some Advantages on Pipeline

Pre-IPO Broncus Holding Corporation - The Strength and the Concerns

Pre-IPO Angelalign Technology - Promising Market but Full of Challenges

Pre-IPO YishengBio Co., Ltd  - Here Are the Concerns Despite Solid Market Potential

Pre-IPO Intco Medical Technology - Economies of Scale or Overcapacity?

Gravity Works As WeWork Doesn't; Now Plan B

Bifurcated Chinese Express Market Developing

Equity Capital Markets

Beijing Keya Medical Technology / Equity Capital Markets

<p>The combination of AI and medical treatment has become a major development trend in the future medical field. In this context, many participants in the AI medical market have more desire for the public capital markets. For example, on March 16, 2021, <a href="https://www.smartkarma.com/entities/beijing-keya-medical-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:32228:1" rel="noopener">Beijing Keya Medical Technology (BKM CH)</a>, an artificial intelligence (AI) medical device company, submitted an application to the Hong Kong Stock Exchange to be listed on the main board. Keya, founded in 2016, is quite favored by capital. Up to now, Keya has completed six rounds of financing. Especially in 2020, it completed four rounds of financing with the amount of nearly RMB900 million. The following mainly analyzed both the strength and the concerns of the Company.</p>

The combination of AI and medical treatment has become a major development trend in the future medical field. In this context, many participants in the AI medical market have more desire for the public capital markets. For example, on March 16, 2021, Beijing Keya Medical Technology (BKM CH), an artificial intelligence (AI) medical device company, submitted an application to the Hong Kong Stock Exchange to be listed on the main board. Keya, founded in 2016, is quite favored by capital. Up to now, Keya has completed six rounds of financing. Especially in 2020, it completed four rounds of financing with the amount of nearly RMB900 million. The following mainly analyzed both the strength and the concerns of the Company.

Pre-IPO Beijing Keya Medical Technology - Here Are the Strength and the Concerns